BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Risbridger GP, Clark AK, Porter LH, Toivanen R, Bakshi A, Lister NL, Pook D, Pezaro CJ, Sandhu S, Keerthikumar S, Quezada Urban R, Papargiris M, Kraska J, Madsen HB, Wang H, Richards MG, Niranjan B, O'Dea S, Teng L, Wheelahan W, Li Z, Choo N, Ouyang JF, Thorne H, Devereux L, Hicks RJ, Sengupta S, Harewood L, Iddawala M, Azad AA, Goad J, Grummet J, Kourambas J, Kwan EM, Moon D, Murphy DG, Pedersen J, Clouston D, Norden S, Ryan A, Furic L, Goode DL, Frydenberg M, Lawrence MG, Taylor RA. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nat Commun 2021;12:5049. [PMID: 34413304 DOI: 10.1038/s41467-021-25175-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Parvin R, Chen M, Hu D, Fan Q, Ye F. High-throughput microfluidic droplets in biomolecular analytical system: A review. Biosens Bioelectron 2023;228:115213. [PMID: 36906989 DOI: 10.1016/j.bios.2023.115213] [Reference Citation Analysis]
2 Jefferi NES, Shamhari A‘, Noor Azhar NKZ, Shin JGY, Kharir NAM, Azhar MA, Hamid ZA, Budin SB, Taib IS. The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches. Biomedicines 2023;11:826. [DOI: 10.3390/biomedicines11030826] [Reference Citation Analysis]
3 Olkowski C, Fernandes B, Griffiths GL, Lin F, Choyke PL. Preclinical Imaging of Prostate Cancer. Semin Nucl Med 2023:S0001-2998(23)00007-7. [PMID: 36882335 DOI: 10.1053/j.semnuclmed.2023.02.002] [Reference Citation Analysis]
4 Sailer V, von Amsberg G, Duensing S, Kirfel J, Lieb V, Metzger E, Offermann A, Pantel K, Schuele R, Taubert H, Wach S, Perner S, Werner S, Aigner A. Experimental in vitro, ex vivo and in vivo models in prostate cancer research. Nat Rev Urol 2023;20:158-78. [PMID: 36451039 DOI: 10.1038/s41585-022-00677-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Miyahira AK, Hawley JE, Adelaiye-Ogala R, Calais J, Nappi L, Parikh R, Seibert TM, Wasmuth EV, Wei XX, Pienta KJ, Soule HR. Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting. Prostate 2023;83:207-26. [PMID: 36443902 DOI: 10.1002/pros.24461] [Reference Citation Analysis]
6 Lawrence MG, Taylor RA, Cuffe GB, Ang LS, Clark AK, Goode DL, Porter LH, Le Magnen C, Navone NM, Schalken JA, Wang Y, van Weerden WM, Corey E, Isaacs JT, Nelson PS, Risbridger GP. The future of patient-derived xenografts in prostate cancer research. Nat Rev Urol 2023. [PMID: 36650259 DOI: 10.1038/s41585-022-00706-x] [Reference Citation Analysis]
7 Zhao Y, Wen S, Li H, Pan CW, Wei Y, Huang T, Li Z, Yang Y, Fan S, Zhang Y. Enhancer RNA promotes resistance to radiotherapy in bone-metastatic prostate cancer by m(6)A modification. Theranostics 2023;13:596-610. [PMID: 36632223 DOI: 10.7150/thno.78687] [Reference Citation Analysis]
8 Ramm S, Vary R, Gulati T, Luu J, Cowley KJ, Janes MS, Radio N, Simpson KJ. High-Throughput Live and Fixed Cell Imaging Method to Screen Matrigel-Embedded Organoids. Organoids 2022;2:1-19. [DOI: 10.3390/organoids2010001] [Reference Citation Analysis]
9 Aizawa Y, Takada K, Aoyama J, Sano D, Yamanaka S, Seki M, Kuze Y, Ramilowski JA, Okuda R, Ueno Y, Nojima Y, Inayama Y, Hatakeyama H, Hatano T, Takahashi H, Nishimura G, Fujii S, Suzuki Y, Taniguchi H, Oridate N. Establishment of experimental salivary gland cancer models using organoid culture and patient-derived xenografting. Cell Oncol 2022. [DOI: 10.1007/s13402-022-00758-6] [Reference Citation Analysis]
10 Lassche G, van Boxtel W, Aalders TW, van Hooij O, van Engen - van Grunsven AC, Verhaegh GW, van Herpen CM, Schalken JA. Development and characterization of patient-derived salivary gland cancer organoid cultures. Oral Oncology 2022;135:106186. [DOI: 10.1016/j.oraloncology.2022.106186] [Reference Citation Analysis]
11 Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J. Preclinical Models of Neuroendocrine Neoplasia. Cancers (Basel) 2022;14. [PMID: 36428741 DOI: 10.3390/cancers14225646] [Reference Citation Analysis]
12 Van Hemelryk A, Tomljanovic I, de Ridder CMA, Stuurman DC, Teubel WJ, Erkens-Schulze S, Verhoef EI, Remmers S, Mahes AJ, van Leenders GJLH, van Royen ME, van de Werken HJG, Grudniewska M, Jenster GW, van Weerden WM. Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling. Cells 2022;11. [PMID: 36429059 DOI: 10.3390/cells11223632] [Reference Citation Analysis]
13 Rajeswaran K, Muzio K, Briones J, Lim-fat MJ, Tseng C, Smoragiewicz M, Detsky J, Emmenegger U. Prostate Cancer Brain Metastasis: Review of a Rare Complication with Limited Treatment Options and Poor Prognosis. JCM 2022;11:4165. [DOI: 10.3390/jcm11144165] [Reference Citation Analysis]
14 Alizadeh-Ghodsi M, Owen KL, Townley SL, Zanker D, Rollin SPG, Hanson AR, Shrestha R, Toubia J, Gargett T, Chernukhin I, Luu J, Cowley KJ, Clark A, Carroll JS, Simpson KJ, Winter JM, Lawrence MG, Butler LM, Risbridger GP, Thierry B, Taylor RA, Hickey TE, Parker BS, Tilley WD, Selth LA. Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer. Cancer Res Commun 2022;2:706-24. [PMID: 36923279 DOI: 10.1158/2767-9764.CRC-21-0139] [Reference Citation Analysis]
15 Hao M, Cao Z, Wang Z, Xin J, Kong B, Xu J, Zhang L, Chen P. Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer. ACS Biomater Sci Eng 2022. [PMID: 35696669 DOI: 10.1021/acsbiomaterials.2c00354] [Reference Citation Analysis]
16 Shi M, Wang Y, Lin D, Wang Y. Patient-derived xenograft models of neuroendocrine prostate cancer. Cancer Lett 2022;525:160-9. [PMID: 34767925 DOI: 10.1016/j.canlet.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Fidelito G, Watt MJ, Taylor RA. Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? Front Oncol 2022;11:778761. [DOI: 10.3389/fonc.2021.778761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Toivanen R, Porter LH, Li Z, Clouston D, Risbridger GP, Taylor RA. Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification. Cancer Lett 2022;524:182-92. [PMID: 34687792 DOI: 10.1016/j.canlet.2021.10.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Thomas T. The MURAL prostate cancer PDX collection. Nat Rev Urol 2021;18:637. [PMID: 34608298 DOI: 10.1038/s41585-021-00528-3] [Reference Citation Analysis]
20 Bevan CL. Breaking down walls in prostate cancer with the MURAL collection of patient-derived xenografts. Nat Commun 2021;12:5504. [PMID: 34535657 DOI: 10.1038/s41467-021-25783-1] [Reference Citation Analysis]